Australian regulators review latest risk advice on AstraZeneca COVID-19 jab
Australia’s medical regulators are urgently reviewing the latest health advice on AstraZeneca’s COVID-19 immunisation.
Change | ||
S&P/ASX Sm. Ords. | |||
All Ordinaries | |||
S&P/ASX 100 |
PPG | PRO-PAC PACKAGING LIMITED | 4.2¢ | 147% |
IVX | INVION LIMITED | 15.0¢ | 30.4% |
CAE | CANNINDAH RESOURCES LIMITED | 6.3¢ | 26.0% |
FND | FINDI LIMITED | $5.91 | 23.7% |
MCM | MC MINING LIMITED | 12.5¢ | 19.4% |
BXN | BIOXYNE LIMITED | 1.5¢ | 16.7% |